论文部分内容阅读
目的探讨肝动脉化疗栓塞联合射频消融治疗原发性肝癌的临床疗效及安全性。方法选取2011年1月至2014年9月间收治的100例原发性肝癌患者,根据随机数字表法分为观察组和对照组,每组50例,观察组患者接受肝动脉化疗栓塞联合射频消融治疗,对照组患者接受肝动脉化疗栓塞治疗。观察和比较两组患者治疗后的临床疗效、肿瘤坏死程度、术后6个月肿瘤复发率、生存率以及不良反应发生情况。结果观察组患者的治疗总有效率和肿瘤完全坏死率明显高于对照组(P<0.05)。平均随访6个月,观察组患者肿瘤复发率明显低于对照组,生存率显著升高(P<0.05)。两组患者治疗期间均未出现严重不良反应。结论肝动脉化疗栓塞联合射频消融治疗原发性肝癌的疗效显著,可明显提高肿瘤坏死率及生存率,不良反应少,安全性好。
Objective To investigate the clinical efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer. Methods One hundred patients with primary liver cancer who were admitted between January 2011 and September 2014 were divided into observation group and control group according to the random number table method, 50 cases in each group. The patients in observation group received hepatic arterial chemoembolization combined with radiofrequency Ablation treatment, control group received hepatic artery chemoembolization. The clinical efficacy, the degree of tumor necrosis, the tumor recurrence rate, the survival rate and the incidence of adverse reactions at 6 months after operation were observed and compared between the two groups. Results The total effective rate of treatment and complete tumor necrosis in observation group were significantly higher than those in control group (P <0.05). The average follow-up of 6 months, the observation group patients with tumor recurrence rate was significantly lower than the control group, the survival rate was significantly increased (P <0.05). Two groups of patients during the treatment did not appear serious adverse reactions. Conclusions The therapeutic effect of transcatheter arterial chemoembolization combined with radiofrequency catheter ablation on primary hepatocellular carcinoma is significant, which can significantly improve the tumor necrosis rate and survival rate with less adverse reactions and good safety.